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To assessthe potentialutilityofpiroximone(MDL-19,205),
an investigational inotrope-vasodilator agent, in severe
heart failure, 15 patients with severe left ventricular
failure refractory to conventional agents were enrolled
in an acute hemodynamic study. After incremental in-
travenous dosing (mean total dose 1.8 ± 0.4 mg/kg body
weight), cardiac index increased (1.7 ± 0.3 to 2.6 ±
0.6 liters/min per m2; p < 0.001) and left ventricular
filling pressure decreased (25 ± 7 to 19 ± 7 mm Hg; p
< 0.001). Also decreasing significantly were right atriai
pressure (13 ± 6 to 7 ± 5 mm Hg; p < 0.005) and
systemic vascular resistance (1,633 ± 394 to 1,183 ±
278 dynes-s-em-5;p < 0.001). Heart rate and mean ar-
terial pressure did not change, whereas stroke work in-
dex increased significantly (13.3 ± 4.3 to 21.6 ± 7.3
g.mlm2; p < 0.005). The increase in stroke work index
with a concomitant decrease in left ventricular filling
pressure indicates an improvement in systolic perform-
ance after treatment with piroximone. Similar responses
were obtained after incremental doses of piroximone in
oral solution. After oral doses of piroximone tablets,
Established therapy for patients with severe congestive heart
failure includes attempts to restore abnormal ventricular
loading conditions toward normal with diuretics and vaso-
dilator agents (I), and may include the use of digitalis to
improve left ventricular contractile function (2). Such ther-
apy is designed to alleviate symptoms by reducing systemic
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cardiac index also increased significantly (2.1 ± 0.6 to
2.4 ± 0.5 liters/min per m2; p < 0.05), although this
magnitude of increase was comparatively low.
In a subgroup of 10 patients who underwent equilib-
rium gated radionuclide blood pool scintigraphy before
and after intravenous piroximone, end-diastolic volume
index tended to increase (106 ± 42 to 132 ± 60 ml/m2;
p =0.07), whereas left ventricular filling pressure de-
creased significantly (26 ± 8 to 19 ± 9 mm Hg; p <
0.01). This suggests an improvement in overall left ven-
tricular distensibility after piroximone treatment. Of the
original 15 patients, 9 died within 2 months of the hemo-
dynamic study; 3 had therapy discontinued after 1 to 14
months because of side effects or lack of clinical im-
provement; and 3 are still alive and receiving oral pi-
roximone after 24 to 27 months of foUow-up. Thus, pi-
roximoneproducesacute hemodynamicimprovementeven
in patients with severe heart failure, but their prognosis
remains poor.
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and pulmonary venous congestion and by improving cardiac
output.
More recently, a number of new agents having both ino-
tropic and vasodilator effects have been used in patients
with severe heart failure. Such agents have included am-
rinone (3,4), milrinone (5,6), ROI3-6438 (7) and enoxi-
mone (MDL 17,043) (8-13). Piroximone (MDL 19,205) is
another new nonglycoside, noncatecholamine imidazole de-
rivative that has been demonstrated in vitro and in experi-
mental animals to have direct inotropic and vasodilator ac-
tions (14,15). Salutary short-term hemodynamic effects of
piroximone were reported (16) in a small group of patients
with severe heart failure. This study was therefore under-
taken to evaluate the hemodynamic effects of intravenous
and oral piroximone in patients with refractory heart failure,
and to assess its potential long-term clinical utility in these
patients.
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Methods
Study patients (Table 1). Fifteen patients with severe
congestive heart failure refractory to conventional therapy
were studied. There were 14 men and I woman with a mean
age of 64 ± 9 years (range 47 to 84). The cause of conges-
tive heart failure was ischemic heart disease in 10 patients
and idiopathicdilated cardiomyopathy in 5. One patient with
cardiomyopathy also had hemodynamically insignificant aortic
insufficiency. Symptoms were severe in all patients; there
were 11 patients in New York Heart Association functional
class IV and 4 in class III. The duration of symptoms was
1 month to 13 years (median 24 months). All patients were
receiving digoxin and diuretics at the time of the study, and
all had previously been treated with one or more vasodilator
agents, including captopril, hydralazine, prazosin and ni-
trates, before the study. Most of the patients had a deteri-
orating cardiac status at the time of the study. All studies
were approved by the institutional Committee on Human
Research, and all patients gave informed consent.
Hemodynamic measurements. Digoxin and diuretics
were continued at maintenance doses but vasodilators were
discontinued 72 hours before the study. Two patients (Pa-
tients 1 and 10) received a dobutamine infusion that was
discontinued only 1 hour before the study because of their
poor clinical status. No patient was receiving any cardi-
otonic or vasodilator drug other than digoxin and diuretics
during this study. A triple lumen, balloon-tipped thermo-
dilution catheter was positioned in the pulmonary artery,
and a small plastic cannula was inserted in the radial artery
for recording arterial pressure. Measured hemodynamic
variables included systolic and diastolic arterial blood pres-
sure (SBP and DBP, respectively, mm Hg); systolic and
diastolic pulmonary artery pressure (PAS and PAD, re-
spectively, mm Hg): pulmonary capillary wedge pressure
(PCWP, mm Hg) and mean right atrial pressure (RAP, mm
Hg). Heart rate (HR, beats/min) was determined from a
simultaneously recorded electrocardiographic (ECG) rhythm
strip. Cardiac output (CO, liters/min) was determined in
triplicate by the thermodilution technique, and the results
were averaged. In several instances, the pulmonarycapillary
wedge pressure was found to be ::;2 mm Hg lower than the
pulmonary artery diastolic pressure; the latter was then used
instead of the wedge pressure as a measure of left ventricular
filling pressure. In these patients, pulmonaryartery diastolic
pressure was used as an index of left ventricular filling
pressure throughout the study.
Calculated hemodynamic variables included: cardiac in-
dex (CI; liters/min per rrr') - CO/BSA where BSA = body
surface area in rrr'; stroke volume index (SVI; ml/rrr') =
CI/HR; mean arterial pressure (MAP; mm Hg) = DBP +
I/,(SBP - DBP); mean pulmonary artery pressure (PAM;
mm Hg) = PAD + l/,(PAS - PAD); systemic vascular
resistance (SVR; dynes-s-cm 5) = 80(MAP - RAP)/CO;
pulmonary vascular resistance (PVR; dynes-s-cm - 5) =
80(PAM - PCWP)lCO and stroke workindex (SWI; g-m/rrr')
= 0.0136(MAP - PCWP) x (SVI).
Intravenous piroximone administration. After cathe-
ter insertion there was a 30 minute rest period, followed by
determinationof two sets of control hemodynamicvariables.
These were averaged to obtain baseline data. Piroximone
was then administered as repeated intravenous infusions of
0.5 mg/kg body weight (over 5 minutes) with hemodynamic
variables determined 10 minutes after completion of each
Table 1. Clinical Characteristics of 15 Patients With Heart Failure Receiving Piroximone
Patient Age (yr) Origin Duration of NYHA Status at Time to Death or
No. & Sex ofCHF Symptoms (mo) Class Follow-Up Last Follow-Up (mo)
) 73M Ischemic I IV Alive 27*
2 62M Idiopathic 60 IV Alive 26*
3 66M Idiopathic 36 IV Alive 14t
with Al
4 63M Idiopathic 48 IV Dead 0.8
5 84M Ischemic 12 IV Dead 0.5
6 63M Ischemic 48 IV Dead 1.6
7 60M Idiopathic 156 IV Alive 1.2t
8 47F Ischemic 24 III Alive 24*
9 54M Ischemic 24 IV Dead 0.5
10 73M Ischemic 24 IV Dead 0.2
II 54M Ischemic II III Dead I
12 12M Idiopathic 12 III Dead 1.3
13 65M Ischemic 24 IV Dead 0.3
14 12M Ischemic 8 IV Alive 8t
15 5IM Ischemic 24 III Dead 0.2
*Still receiving piroximone. [Months until piroxirnone discontinued. AI aortic insufficiency; CHF = congestive heart failure; F = female;
Idiopathic = idiopathic cardiomyopathy; Ischemic = ischemic cardiomyopathy; M = male; NYHA class = New York Heart Association functional
class.
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infusion. According to the protocol, doses were given ap-
proximately 15 minutes apart and were repeated until: I) a
maximum of 2.0 to 2.5 mg/kg had been administered; 2) a
plateau in cardiac output response was observed; 3) systolic
blood pressure decreased by >20% or to <85 mm Hg or
heart rate increased by > 15% or to > 120 beats/min or
pulmonary wedge pressure decreased to < 10 mm Hg; or 4)
significant adverse effects occurred. The mean total intra-
venous dose was 1.8 ± 0.4 mg/kg (range 1.0 to 2.5), and
the only patient (Case 4) who received 2.5 mg/kg developed
significant hypotension, which required dopamine therapy.
Hemodynamic measurements takenafterdopamine was started
were not included for analysis. Hemodynamic measure-
ments were made at 10, 30 and 60 minutes after the last
dose, and then hourly for 3 more hours or until those mea-
surements had returned to baseline.
Radionuclide scintigraphy. A subgroup of 10 patients
underwent technetium-99m pyrophosphate blood pool scin-
tigraphy at the time of the control hemodynamic measure-
ments, and again at the time of the peak response of cardiac
index. None of these IOpatients had clinically evident sig-
nificant mitral regurgitation. Ejection fraction (EF) was de-
termined at baseline and peak hemodynamic effect using
standard methods based on radioactive counts (17). Ven-
tricular volumes were then calculated as follows: end-dia-
stolic volume index (EDVI; ml/rrr') = SVIIEF and end-
systolic volume index (ESVI; ml/rrr') = EDVI - SVI,
where SVI is stroke volume index in ml/rrr'.
Piroximone oral solution administration. After hemo-
dynamic variables had returned to baseline values, at least
6 hours after the last intravenous dose, therapy with pirox-
imone in an oral solution formulation was started. Fourteen
patients received piroximone oral solution; Patient 4 had
become markedly hypotensive after intravenous therapy and
was excluded from oral therapy. After control measurements
were taken, incremental oral doses of 0.5 mg/kg of pirox-
imone solution were administered, every 30 minutes, to a
total dose of 2.0 mg/kg. Hemodynamic variables were de-
termined at 30 and 60 minutes after the fourth dose of oral
solution, and then hourly for 3 additional hours.
Piroximone tablet administration. At least 6 hours after
the last dose of piroximone solution, piroximone tablet ther-
Table 2. Change in Cardiac Index After Piroximone Administration*
apy was begun. Fourteen patients received the tablets (Pa-
tient 4 was excluded as described previously), but hemo-
dynamic variables were determined in 13. The initial tablet
dose was approximately 1 mg/kg (one 50, 75 or 100 mg
tablet). Hemodynamic variables were then measured hourly
for 6 hours. Additional tablet doses were then given every
6 hours, to a maximum of 100 mg/dose. The mean maximal
tablet dose was 90 ± 15 mg (nine patients received 100
mg, three received 75 mg and one received 50 mg as the
maximal tablet dose).
Clinical follow-up. The 14 patients given oral piroxi-
mone were continued on this therapy until death, clinical
deterioration or adverse effects supervened. Patients were
evaluated weekly for the first month and at least monthly
thereafter.
Statistical analysis. The statistical significance of changes
in hemodynamic variables was determined by analysis of
variance with repeated measures, with the significance level
defined as probability (p) < 0.05.
Results
Hemodynamic effects. Peak effect was defined as the
highest cardiac output achieved after the maximal dose of
piroximone, and the other hemodynamic variables were ana-
lyzed at the time of the maximal increase in cardiac output.
Table 2 gives the time course of change in cardiac index
after piroximone administration by three different routes
(intravenous, oral solution and tablets). After treatment with
intravenous piroximone, cardiac index increased signifi-
cantly, from 1.7 ± 0.3 at baseline to 2.5 ± 0.5 liters/min
per nr', both 10 minutes after the first dose and 30 minutes
after the maximal dose (p < 0.00 I). Similarly, administra-
tion of oral piroximone in a liquid formulation produced a
significant increase in cardiac index, from 1.9 ± 0.3 at
baseline to 2.4 ± 0.6 liters/min per rrr'measured 30 minutes
after the maximal dose. On the other hand, cardiac index
increased only modestly at I hour after tablet administration,
possibly because of a residual piroximone effect at the time
of tablet dosing.
Table 3 summarizes the change in hemodynamic vari-
ables after treatment with intravenous piroximone. In ad-
Route of
Time After Piroximone Administration
Administration Control 10 Minutes 30 Minutes I Hour 2 Hours 3 Hours 4 Hours
Intravenous (n = 15) 1.7 ± 0.3 2.5 ± 0.5t 2.5 ± 0.5t 2.3 ± OAt 2.1 ± OAt 1.9 ± 0.5 1.9 ± 0.5
Oral
Solution (n = 14) 1.9 ± 0.3 204 ± 0.6t 204 ± OAt 2.2 ± 0.5 2.1 ± 0.5 2.0 ± 0.6
Tablets (n = 13) 2.1 ± 0.6 2.4 ± 0.5 2.4 ± 0.6 2.2 ± 004 2.2 ± 0.3
*Data shown are values of cardiac index (liters/min per rrr') at the indicated time; tp < 0.001 versus control; tp < 0.05 versus control; n = Number
of patients.
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Table3. Changes in Hemodynamic Variables in 15 Patients After Intravenous Piroximone
Control Peak Effect p Value
HR (beats/min) 90 ± J7 92 ± 16 NS
RAP (mm Hg) 13 ± 6 7 ± 5 <0.005
PAM (mm Hg) 35 ± 8 29 ± 10 NS
LVFP (mm Hg) 25 ± 7 19 ± 7 <0.001
MAP(mm Hg) 73 ± 6 73 ± 8 NS
CI (liters/min per rrr') 1.7 ± 0.3 2.5 ± 0.5 <0.001
SVR (dynes.s-em-5) 1633 ± 394 1183 ± 278 <0.001
PVR (dynes-s-cm _. 5) 304 ± 164 192 ± III <0.005
SVI (ml/rrr') 20 ± 6 30 ± 8 <0.001
SWI (g-m/m'') 13 ± 4 22 ± 7 <0.005
CI = cardiac index; HR = heart rate; LVFP = left ventricular filling pressure; MAP = mean arterial
pressure; PAM = mean pulmonary artery pressure; PVR pulmonary vascular resistance; RAP = mean right
atrial pressure; SVI = stroke volume index; SVR = systemic vascular resistance; SWI = stroke work index.
Table 4. Changes in Hemodynamic Variables in 14 Patients
After Piroximone Oral Solution
dition to the increase in cardiac index, there were significant
increases in stroke volume index and stroke work index and
significantdecreases in mean right atrial pressure, left ven-
tricular filling pressureand systemicand pulmonary vascular
resistances.
Results after administration of piroximone oral solution
were generally similar (Table 4), with the exception that
the decrease in right atrial pressure (13 ± 6 to 10 ± 6 mm
Hg) was not statistically significant. The hemodynamic
changes after piroximone tablet administration are sum-
marized in Table 5. In general, the hemodynamic effects
were similar to those after administration of oral solution.
However, cardiac index increased only slightly and there
was no significant change in stroke volume and stroke work
indexes. Reduction in systemic vascular resistance was not
significant; right atrial and pulmonary artery pressures and
left ventricular filling pressure decreased significantly.
Effects on left ventricular performance. Left ventric-
ular systolicperformanceimprovedafter intravenous admin-
istrationof piroximone, as indicatedby an increase in stroke
volume index (20 ± 6 to 30 ± 8 ml/rn", p < 0.001), with
a concomitant decrease in left ventricular filling pressure
(25 ± 7 to 19 ± 7 mm Hg, p < 0.01). Figure I depicts
Abbreviations as in Table 3.
Peak Effect p Value
individual patient data for the relation between stroke vol-
ume index and left ventricular filling pressure before and at
peak effect after intravenous piroximone treatment. Twelve
of these 15 patients demonstrated a shift in this relation
upward and to the left, suggesting improvement in left ven-
tricularsystolic function. In the subgroupof 10patients who
had scintigraphic evaluation, ejection fraction did not change
significantly (0.22 ± 0.09 to 0.24 ± 0.09, P = NS),
although the short-term hemodynamic effects were similar
to those of the entire group of 15 patients.
Effects on left ventricular diastolic function. Shown
in Figure 2 are the individual patient data for the relation
betweenend-diastolic volume index and left ventricular fill-
ing pressure, at baseline and peak effect, in the subgroup
of 10 patients who underwent radionuclide blood pool scin-
tigraphy during intravenous dosing. The group mean left
ventricular filling pressure decreased (26 ± 8 to 19 ± 9
mm Hg, p < 0.0 I), whereas end-diastolic volume index
tended to increase (106 ± 42 to 132 ± 60 ml/rn", p =
0.07). Eight of 10 patients demonstrated a decrease in left
ventricular filling pressure associated with either no change
or an increase in end-diastolic volume index. This suggests
that intravenous piroximone produces an improvement in
overall left ventricular distensibility.
To further elucidate the potential mechanism of this im-
provement, mean right atrial pressure (RAP, mm Hg) was
used as an estimate of pericardial pressure (18). The trans-
mural left ventricular filling pressure (mm Hg) (LVFP) was
then estimated as LVFP - RAP. Figure 3 displays the
individual patient data for the relation between the change
in transmural left ventricular filling pressure and the change
in end-diastolic volume index, from control to peak effect
after intravenous piroximone treatment. Data points in the
right lower quadrant of Figure 3 denote patients having an
increase in end-diastolic volume index associated with a
decrease in transmuralleft ventricularfilling pressure. There
are five such patients and these are five of the eight patients
demonstrating an improvement in overall left ventricular
NS
NS
NS
<0.01
NS
<0.001
<0.001
<0.05
<0.01
<0.01
97 ± 23
10 ± 6
31 ± 9
21 ± 7
75 ± 9
2.6 ± 0.5
1,200 ± 313
201 ± 95
28 ± 9
20 ± 7
Control
90 ± 20
13 ± 6
36 ± 9
27 ± 8
73 ± 9
U ± 0.3
1,506 ± 328
278 ± 106
22 ± 6
14 ± 5
HR (beats/min)
RAP (mm Hg)
PAM (mm Hg)
LVFP (rnrn Hg)
MAP (mm Hg)
CI (liter/min per rrr')
SVR (dynes-s-crn t '}
PVR (dynes-s-cm -5)
SVI (ml/m2)
SWI (g'm/m2)
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Table 5. Changes in Hemodynamic Variables in 13 Patients After Piroximone Oral Tablets
Control I Hour p Value
HR (beats/min)
RAP (mm Hg)
PAM (mm Hg)
LVFP (mm Hg)
MAP (mm Hg)
CI (liters/min per m')
SVR (dynes-s-cm - ')
PVR (dynes-s-cm - ')
SVI (rnl/m')
SWI (g-rn/rn')
93 ± 15
13 ± 7
37 ± 7
26 ± 6
77 ± 8
2.1 ± 0.6
1,466 ± 389
265 ± 173
23 ± 7
16 ± 6
95 ± 18
8 ± 5
32 ± 8
22 ± 6
74 ± II
2.4 ± 0.5
1,284 ± 367
203 ± 162
26 ± 6
18 ± 5
NS
<0.01
<0.005
<0.01
NS
<0.05
NS
<0.01
NS
NS
Abbreviations as in Table 3.
(I patient) or the appareance of nonsustained (2 patients)
or sustained (I patient) ventricular tachycardia. Gastroin-
testinal symptoms, including nausea and anorexia, occurred
in three patients during oral tablet therapy.
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Figure 2. Relation between left ventricular filling pressure (LVFP)
and end-diastolic volume index (EDVI) in 10 patients before (cir-
cles) and after (arrowheads) intravenous piroximone. Mean data
are depicted by open squares before (A) and after (B) piroximone.
In 8 of the 10 patients, there is a shift in this relation downward
and to the right, indicating improvement in left ventricular dis-
tensibility.
Discussion
Hemodynamic effects of intravenous piroximone. The
short-term hemodynamic effects of piroximone have pre-
viously been reported by Petein et al. (16) in a group of
eight patients with severe heart failure. Intravenous doses
of 1.25 to 1.75 mg/kg produced a statistically significant
increase in cardiac index, and significant decreases in pul-
monary capillary wedge pressure, right atrial pressure and
40
r-.
C\J
E
<,
"E 20
'--'
>(f)
0
LVFP (rnrn Hg)
Figure 1. Relation between stroke volume index (SVI) and left
ventricular filling pressure (LVFP) in 15 patients before (closed
circles) and after (arrowheads) intravenous piroximone. Mean
data are depicted by open squares before (A) and after (B) pi-
roximone. There is an increase in stroke volume index with a
concomitant decrease in left ventricular filling pressure, indicating
improvement in left ventricular function.
distensibility in Figure 2. Thus, for these five the improve-
ment in left ventricular distensibility does not appear to be
due to ventricular interaction mediated by a reduction in
pericardial pressure, and other mechanisms must be oper-
ative.
Clinical follow-up. Table I summarizes the clinical out-
come of this group of IS patients with severe heart failure.
Nine patients (60%) died within 2 months of the study.
Three patients (Cases 3, 7 and 14) were alive at the time
the drug was discontinued (at 14, I and 8 months, respec-
tively, after the study) because of lack of clinical improve-
ment. Three additional patients (Cases I, 2 and 8) are still
alive and receiving piroximone therapy (at 27, 26 and 24
months, respectively, after the hemodynamic study).
Side effects. Adverse effects were not uncommon during
piroximone therapy. With intravenous piroximone, 4 of 15
patients demonstrated apparent worsening of ventricular ar-
rhythmias, including an increase in ventricular ectopic beats
JACC Vol. 9. NO.5
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Figure 3. Relation between change in transmural left ventricular
filling pressure [A(LVFP - RAP)1and change in end-diastolic
volumeindex (AEDVI) after intravenous piroximone. Data points
in the right lower quadrant denote 5 patients having increased
end-diastolic volume index with a concomitant decrease in trans-
mural left ventricular filling pressure, suggesting that reduction in
pericardial pressuredoes not accountfor apparentimprovement in
left ventriculardistensibility in these patients. RAP = mean right
atrial pressure.
systemic vascular resistance. The relation between stroke
volume index and left ventricular filling pressure was shifted
upward and to the left after piroximone treatment, indicating
improved left ventricular performance. In another group of
four patients, intravenous piroximone produced a 35% in-
crease in the rate of rise of left ventricular pressure (dP/dt),
suggesting a direct inotropic effect of the drug.
Our results with intravenous piroximone in 15 patients
with severe chronic heart failure were generally similar to
those reported by Petein et al. (16) . We observed that cardiac
index increased significantly, whereas left ventricular filling
pressure, right atrial pressure and systemic vascular resist-
ance decreased significantly.
Oral piroximone administration. We have also ex-
tended the observations of Petein et at. (16) to include the
hemodynamic effects of oral piroximone. When adminis-
tered in a liquid preparation, oral piroximone produced
hemodynamic effects of a magnitude similar to that of in-
travenous administration. However, the tablet formulation
of piroximone produced a modest but statistically significant
increase in cardiac index (2.1 ± 0.6 to 2.4 ± 0.5 liters/min
per rrr', p < 0.05). This could possibly be due to inadequate
gastrointestinal absorption of the drug in this formulation,
but only measurement of plasma piroximone levels could
confirm or refute this possibility. Alternatively, although
tablet doses were generally administered more than 6 hours
after the last dose of oral solution, it is possible that a
persistent effect of previous drug administration produced
an elevation of the baseline cardiac index to 2.1 ± 0.6
liters/min per m", and that no further increase was then seen
after tablet dosing.
Adverse effects. In contrast to Petein et at. (16), who
noted no adverse effects during drug administration, we
observed a worsening of ventricular arrhythmias in four
patients, including one who required amiodarone therapy
for symptomatic sustained ventricular tachycardia. Of course,
in this severely ill group of patients, ventricular arrhythmias
are not unusual, so the exact relation between the apparent
worsening of arrhythmias and piroximone administration
cannot be inferred with certainty .
In addition, we observed gastrointestinal side effects of
anorexia and nausea in 3 of 13 patients treated on a long-
term basis with piroximone tablets. Kereiakes et at. (9)
similarly reported an approximately 30% incidence of an-
orexia and nausea in a group of patients treated on a long-
term basis with enoximone, another inotropic agent similar
in structure to piroximone. These effects are perhaps related
to the phosphodiesterase-inhibiting property of both of these
agents (9,16). Although such side effects might respond to
dosage reduction (16), in two of our patients they resulted
in discontinuation of therapy.
Effects on left ventricular distensibility. The relation
between the left ventricular filling pressure and end-diastolic
volume index was assessed in 10 of our patients who under-
went radionuclide angiography before and after intravenous
piroximone therapy (Fig. 2). In eight of these patients, there
was either no change or an increase in end-diastolic volume
after piroximone treatment, despite a fall in left ventricular
filling pressure, suggesting an improvement in overall left
ventricular distensibility after piroximone. A similar effect
was observed by Kereiakes et at. (10) after intravenous
administration of enoximone. To elucidate whether this im-
provement in distensibility might be due to ventricular
interaction mediated by a reduction in intrapericardial pres-
sure, we used the mean right atrial pressure as an estimate
of pericardial pressure. Smiseth et al. (18) demonstrated an
excellent correlation between pericardial pressure and right
atrial or right ventricular diastolic pressure in anesthetized
dogs. We therefore subtracted the right atrial pressure from
the left ventricular filling pressure to obtain the transmural
filling pressure. We then plotted (Fig. 3) the relation be-
tween the change in transmural filling pressure and the change
in end-diastolic volume index. Five of the eight patients
who showed an improvement in left ventricular distensibility
(Fig. 2) also showed an increase in end-diastolic volume
associated with a decrease in transmural filling pressure
(Fig. 3). Thus, in these patients the observed improvement
in distensibility persists even after accounting for the re-
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duction in pericardial pressure, suggesting that this cannot
be the only mechanism of improvement in distensibility.
Conclusion. Piroximone produces substantial hemody-
namic improvement whenadministered intravenously or or-
ally to patients with severe heart failure. An apparent im-
provement in left ventricular distensibility also occurs in
some patients. Despite these improvements, however, the
mortality rate remains high in this severely ill group of
patients with refractory heart failure.
We thank Gunnard Modin for providing the statistical analysis, Beverly
Atherton and the nursing staff of the coronary care unit for research as-
sistance, Pamela Kimball for expert editorial work and Mary Helen Briscoe
for medical illustration.
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